| Autor: |
Johari V; Advocate, Courtyard Attorneys, 47/1345, MIG Adarsh Nagar, Worli, Mumbai 400 030 INDIA., Srinivasan S; Independent Journalist, 8, Seadoll, 54 Chimbai Road, Bandra West, Mumbai 400 050 INDIA. |
| Jazyk: |
angličtina |
| Zdroj: |
Indian journal of medical ethics [Indian J Med Ethics] 2024 Jul-Sep; Vol. IX (3), pp. 175-179. |
| DOI: |
10.20529/IJME.2024.041 |
| Abstrakt: |
In April 2024, in a class action suit for compensation to families of persons suffering injury or death after vaccination with AstraZeneca's (AZ) Covid-19 vaccine [1], the manufacturer admitted in a UK court that the Oxford-AZ Covid-19 vaccine could cause a rare and potentially fatal blood clotting disorder ("thrombosis with thrombocytopenia syndrome" or TTS, which when triggered by a vaccine is called "vaccine induced thrombocytopenia and thrombosis, or VITT) [2]. The AZ Covid-19 vaccine is a chimpanzee adenovirus vectored vaccine encoding the SARS-CoV2 spike protein (ChAdOx1-S) marketed under the names Covishield and Vaxzevria. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
